A mother's voice is the first thing we hear from the time we exit the womb. And its the voice we continue to hear throughout our lives. We model our mother's voice when we first learn to talk. The same voice guides us as we begin to walk. It warns you of potential harm and radiates warmth when you need consolation.
On Monday, April 27, 2015, American theatre director, choreographer, film director and performer Susan Stroman hosted the Alzheimer’s Drug Discovery Foundation’s (ADDF) Ninth Annual Connoisseur’s Dinner at Sotheby’s in New York City. Co-chaired by Leonard A. Lauder of the Estée Lauder cosmetics family, the black-tie event featured fine wine, food and art. More than $2.8 million was raised to support Alzheimer's drug discovery and development
On Wednesday, April 15, 2015, renowned journalist and NPR host Diane Rehm welcomed guests to the Alzheimer’s Drug Discovery Foundation’s (ADDF) Fifth Annual Great Ladies Luncheon & Fashion Show at The Ritz-Carlton in Washington, DC. Rehm, who has long used her public platform to raise awareness for Alzheimer’s disease, spoke eloquently about the need to increase support for drug discovery for Alzheimer’s. She also expressed hope for the future, noting that “there are hundreds of new, potentially disease-modifying drugs in the pipeline.”
Asceneuron SA, an emerging leader in the development of novel, oral small molecule therapeutics targeting tauopathies for Alzheimer’s and related neurodegenerative diseases, today announced that the Alzheimer’s Drug Discovery Foundation (ADDF) awarded it a $325,000 grant to support the development of Asceneuron’s tau modulators.
The Alzheimer’s Drug Discovery Foundation (ADDF) announced today that it has awarded $1 million to GliaCure, a biotechnology company developing innovative therapies based on glial targets, to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer’s disease. The study, which recently began screening volunteers, will determine the safety and tolerability of GliaCure’s primary clinical candidate, GC021109. It follows a 2014 Phase 1a trial which showed GC021109 to be safe and well tolerated in healthy volunteers.
The Alzheimer’s Drug Discovery Foundation (ADDF) is pleased to announce that it is an Official Charity Partner of the 2015 TCS New York City Marathon. The ADDF invites runners who did not secure an individual spot in the 2015 TCS New York City Marathon to join its Runners for Alzheimer’s Research team on Sunday, November 1, 2015.
The Alzheimer’s Drug Discovery Foundation (ADDF) and Pfizer’s Centers for Therapeutic Innovation (CTI) announced today a collaboration designed to advance the development of new small-molecule drugs for Alzheimer’s disease and related dementias. As part of the first-of-its kind collaboration in Alzheimer’s, the ADDF and CTI will jointly invest in translational research projects, with a focus on novel Alzheimer’s drug targets.
The Alzheimer’s Drug Discovery Foundation (ADDF) announced today a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. The grant will support the initiation of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment (aMCI). aMCI is a condition in which memory is worse than to be expected for a person’s age and is considered the pre-dementia stage of Alzheimer’s disease. This is the second grant that the ADDF has made to AgeneBio.
The Alzheimer’s Drug Discovery Foundation (ADDF) and Axxam SpA (Axxam) announced today that ADDF has awarded a follow-on grant to Axxam to further develop small molecule drugs to treat Alzheimer’s disease by targeting inflammation. This grant follows two previous awards by ADDF to Axxam in 2011 and 2013. The award will continue to fund a drug discovery project to identify compounds that selectively block the purinergic receptor, P2X7, which is involved in inflammation in the brain. Research activities under the previous grants have identified a new class of promising P2X7 selective antagonists that are currently under full expansion as well as lead compounds suitable for in vivo assessment in pharmacological models.
Today, the Alzheimer’s Drug Discovery Foundation (ADDF) and the Alzheimer’s Society UK announced new funding to explore the possibility of using a commonly prescribed drug which treats erectile dysfunction as the next treatment for dementia. Tadalafil – part of the same class of drugs as Viagra – is to be one of the major research programs funded by the two charities in a cross-Atlantic research partnership. This is the first ever study researching the use of an erectile dysfunction drug for vascular dementia.